Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 27
- Rutledge JA Crouch JB 1919 The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium. Am Rev Tuberc 2 755 763
- Loewenstein E 1931 Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1 127
- Jensen KA 1932 Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen. Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt 1 222
- Hamel GH 1928 Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee). Zeitschr Tuberk 51 497 531
- Meidell B 1931 Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung. Skandinavisk aktuarietidskrift 14 217 230
- Anonymous 1936 The expectation of life of the tuberculous. Tubercle 17 171 172
- Oldenburg F Seïsoff C 1931 Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen. Zeitschr Tuberk 61 334 349
- Phillips S 1964 Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956. Am Rev Respir Dis 90 61 66 14178627
- May W 1928 Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen? Zeitschr Tuberk 51 177 184
- Ruge H 1909 Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge. Zeitsch Tuberk 15 146 168
- Saegler E 1934 Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter. Zeitschr Tuberk 71 285 288
- Stadler E 1903 Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung. Deutsch Arch Klin Med 95 412 440
- Stephens MG 1941 Follow-up of 1041 tuberculous patients. Am Rev Tuberc 44 451 462
- Holst PF Nicolaysen L Ustvedt Y 1906 Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen. Deutsch Arch Klin Med 88 325 350
- Braeuning H 1920 Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung. Zeitschr Tuberk 33 129 136
- De Besche AD Jørgenson JO 1925 Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer. Norsk Magazin for Laegevidenskaben 86 1229 1253
- Hamel GH 1912 Tuberkulosearbeiten aus dem Kaiserlichen Gesundheitsamte. Deutsche Heilstätten für Lungenkranke. Geschichtliche und statistische Mitteilungen V. 13. Heft. Berlin, Germany Springer Verlag 124
- Van Joost CRNF 1935 Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose. Geneeskund Tijdschr v Ned Indië 75 1223 1235
- Van Vliet B 1963 Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961. Ned Tijdschr Geneesk 107 2180 2181 14094561
- Pamra SP Goyal SS Mathur GP 1973 Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years. Ind J Tuberc 20 57 64
- Sinding-Larsen CMF 1937 On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932. Acta Med Scand 91 39 132
- Magnusson S 1938 Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden. Acta Tuberc Scand 12 201 263
- Münchbach W 1933 Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen. Tuberkulose-Bibliothek 49 64
- Braeuning H Neissen A 1936 Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens. Zeitschr Tuberk 75 305 323
- Braeuning H Neissen A 1933 Die Prognose der offenen Lungentuberkulose. Tuberkulose-Bibliothek 52 40
- Griep WA 1939 De prognose van de open longtuberculose. [Thesis] Amsterdam University of Amsterdam 87
- Braeuning H 1930 Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose. Zeitschr Tuberk 59 109 111
Cited by
Items 301–400 of 630
Kendall, E. A., Malhotra, S., Cook-Scalise, S., Denkinger, C. M., & Dowdy, D. W. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4429-x · Cited by 7
Mahasha, P. W., Ndwandwe, D. E., Mavundza, E. J., Shey, M. S., & Wiysonge, C. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027033 · Cited by 7
Uppal, A., Oxlade, O., Nsengiyumva, N. P., N’Diaye, D. S., Alvarez, G. G., & Schwartzman, K. (2021) · BMC Public Health · doi:10.1186/s12889-021-10187-z · Cited by 7
Irfani, T. H., Fitri, A. D., Roflin, E., Siburian, R., & Umar, T. P. (2021) · Public Health of Indonesia · doi:10.36685/phi.v7i1.397 · Cited by 7
Sensitivity analysis of a model for tuberculosis
Hickson, R., Mercer, G., & Lokuge, K. (2011) · International Congress on Modelling and Simulation (MODSIM) · doi:10.36334/modsim.2011.b2.hickson · Cited by 7
A review of the efficacy of clinical tuberculosis vaccine candidates in mouse models
del Pozo-Ramos, L., & Kupz, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609136 · Cited by 6
Ribeiro, R., Gonçalves, L. A. P., Havik, P. J., & Craveiro, I. M. R. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19073834 · Cited by 6
“It is an air-borne infectious disease with a slow progression [2], typically affecting the lung; nevertheless, 16% out of 7.”
BackgroundMalhotra, A., Ryckman, T. S., Johnson, K., Uhlig, E., Creswell, J., Kendall, E. A., Dowdy, D. W., & Sohn, H. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae019 · Cited by 6
Ge, S., Liu, K., Jiang, X., Feng, Z., Chen, S., Feng, Y., Jiang, G., Yu, Z., Song, L., Shao, L., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf275 · Cited by 8
“A previous study suggested that the natural course of TB, from onset to cure or death, is approximately 3 years [13].”
Cost-effectiveness of TB diagnostic technologies in Ethiopia: a modelling study
Assebe, L. F., Kumsa, A., Fikadu, L., Alemu, B., Baruda, Y. S., & Jiao, B. (2024) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-024-00544-1 · Cited by 6
Amuge, P. M., Becker, G. L., Ssebunya, R. N., Nalumansi, E., Adaku, A., Juma, M., Jackson, J. B., Kekitiinwa, A., Elyanu, P., Wobudeya, E., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301107 · Cited by 6
Mahawan, N., Rattananupong, T., Sri-Uam, P., & Jiamjarasrangsi, W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305264 · Cited by 6
Bayesian inference of reproduction number from epidemiological and genetic data using particle MCMC
Gill, A., Koskela, J., Didelot, X., & Everitt, R. G. (2025) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1093/jrsssc/qlaf065 · Cited by 7
“The death rate used was γ = 1 / 3 to reflect a removal time of 3 years (Tiemersma et al., 2011).”
Sinha, A., Eniyan, K., Sinha, S., Lynn, A. M., & Bajpai, U. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.03.003 · Cited by 6
“3 millions of life in a year according to a recent statistical data [1,2].”
BackgroundOne-month immunotherapy trial in treatment-failed TB patients
Arjanova, O. V., Butov, D., Prihoda, N. D., Zaitzeva, S. I., Yurchenko, L. V., Sokolenko, N. I., Stepanenko, A., Butova, T., Grinishina, E. A., Maksimenko, O. А., et al. (2011) · Open Journal of Immunology · doi:10.4236/oji.2011.12006 · Cited by 6
“The length of therapy, coupled with side effects, often results in poor patient adherence, treatment failure, and the emergence of drug resistance [2].”
BackgroundYimer, S. A., Holm‐Hansen, C., Storla, D. G., & Bjune, G. A. (2014) · Tropical Medicine & International Health · doi:10.1111/tmi.12246 · Cited by 6
“TB management time and the total infectious period for the undiagnosed cases were calculated based on results from previous local studies in Ethiopia (Shargie et al. 2006; Zeleke & Fasil 2011) and a systematic review by Tiemersma et al. (2011).”
MethodKamchedzera, W., Maheswaran, H., Squire, S. B., Joekes, E. C., Pai, M., Nliwasa, M., Lalloo, D. G., Webb, E. L., Corbett, E. L., & MacPherson, P. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16683.1 · Cited by 6
Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation
Shimoda, M., Yoshiyama, T., Okumura, M., Tanaka, Y., Morimoto, K., Kokutou, H., Osawa, T., Furuuchi, K., Fujiwara, K., Ito, K., et al. (2022) · Medicine · doi:10.1097/md.0000000000029297 · Cited by 6
“Pulmonary tuberculosis (TB) is a slowly progressive disease caused by Mycobacterium tuberculosis([1]) and is associated with lower levels of inflammatory markers, such as C-reactive protein (CRP), than community-acquired pneumonia.”
BackgroundKim, H. N., Lee, J., Yoon, S., Jang, W. S., & Lim, C. S. (2023) · Diagnostics · doi:10.3390/diagnostics13081497 · Cited by 6
“Without treatment, the mortality rate for tuberculosis (TB) is high, reaching approximately 50% [2].”
BackgroundImagerie de la tuberculose pulmonaire
Fock-Yee, C., Beigelman‐Aubry, C., Daou, S., Soussan, M., Brauner, M., Bouvry, D., & Brillet, P. (2015) · Feuillets de Radiologie · doi:10.1016/j.frad.2015.06.004 · Cited by 6
Dibissa, K. E., Waktole, Z. D., & Tolessa, B. E. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/869727 · Cited by 6
Profil épidémiologique de la Tuberculose, Sénégal, 2009-2018
Sow, K. D., Yanogo, P. K., Ndiaye, M., Kane, M., Sawadogo, B., Otshudiandjeka, J., Laurent, M., Diallo, F., Ndir, A., & Méda, N. (2021) · Journal of Interventional Epidemiology and Public Health · doi:10.37432/jieph.supp.2021.4.4.03.12 · Cited by 5
Khoda, P., Bajiya, V. P., Prasad, S. N., & Meena, O. P. (2025) · Journal of Applied Mathematics and Computing · doi:10.1007/s12190-025-02659-x · Cited by 5
“The incubation period for tuberculosis (TB) typically ranges from 2 to 10 weeks, though it may be longer, and individuals are usually asymptomatic during this time [46].”
Ledesma, J. R., Zhang, M., Liew, M. F., Dominguez, R.-M. V., Whikehart, S. M., Verma, M., Ma, J., Movo, A., Chu, H. T., Ostroff, S. M., et al. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(26)00295-1 · Cited by 8
Widoyo, R., Djafri, D., Putri, A. S. E., Yani, F. F., Kusumawati, R. L., Wongsirichot, T., & Chongsuvivatwong, V. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8010031 · Cited by 5
“The case fatality rate of untreated bacteriologically confirmed tuberculosis ranges from 0% to 82% [2].”
BackgroundNuwematsiko, R., Kiwanuka, N., Wafula, S. T., Nakafeero, M., Nakanjako, L., Luzze, H., Turyahabwe, S., Sekandi, J. N., Atuyambe, L. M., & Buregyeya, E. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-12115-4 · Cited by 5
“The lack of timely treatment initiation for TB patients increases the severity of the disease and the likelihood of poor treatment outcomes [14, 16, 39, 40].”
Ayele, B., & Nenko, G. (2015) · Mycobacterial Diseases · doi:10.4172/2161-1068.1000194 · Cited by 5
“Despite the availability of highly effective treatment for decades, tuberculosis (TB) remains a major global health problem [1].”
BackgroundQuality of life among tuberculosis patients on treatment in Southwest Nigeria
Bamidele, J., Abiodun, O. A., Sodeinde, K. J., & Daniel, O. J. (2023) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2023.04.009 · Cited by 5
Hacking, D., & Cleary, S. (2016) · Health Research Policy and Systems · doi:10.1186/s12961-016-0081-8 · Cited by 5
“Furthermore, those who survive can still be disabled by TB for as long as 10 years and TB is mostly a disease of young to middle-aged adults [20].”
BackgroundTuberculosis among transhumant pastoralist and settled communities of south-eastern Mauritania
Lô, A., Tall-Dia, A., Bonfoh, B., & Schelling, E. (2016) · Global Health Action · doi:10.3402/gha.v9.30334 · Cited by 5
“2 years) likely underestimate the duration of disease (14).”
BackgroundFirrantello, J., & Bahnfleth, W. P. (2017) · Science and Technology for the Built Environment · doi:10.1080/23744731.2017.1409267 · Cited by 5
“However, the length of a tuberculosis infection is about 3 years (Tiemersma et al. 2011), making the overall effect of a single incident much more severe.”
BackgroundWang, Y., Wu, Q., Zhang, W., & Zhang, N. (2018) · Current Bioinformatics · doi:10.2174/1574893613666180621153734 · Cited by 5
Vinh, D. N., Hà, Đ. T. M., Hanh, N. T., Thwaites, G. E., Boni, M. F., Clapham, H., & Thương, N. T. T. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3383-3 · Cited by 5
Zwick, E. D., Pepperell, C. S., & Alagöz, O. (2021) · Medical Decision Making · doi:10.1177/0272989x211007842 · Cited by 5
“In addition, untreated active disease lasts on average 2 to 3 y until death or self-cure.(20) To capture this wide range of latent and active disease times, we have modeled minimum time steps of 1 mo.”
BackgroundBasic and Descriptive Epidemiology of Tuberculosis
Dowdy, D. W., & Raviglione, M. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-66703-0_4 · Cited by 5
EPSP Synthase-Depleted Cells Are Aromatic Amino Acid Auxotrophs in Mycobacterium smegmatis
Duque-Villegas, M. A., Abbadi, B. L., Romero, P. R., Matter, L. B., Galina, L., Dalberto, P. F., Rodrigues-Junior, V. S., Ducati, R. G., Roth, C. D., Rambo, R. S., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00009-21 · Cited by 7
“Samples were collected before induction (PAM2, 0 h) or 18h after induction (PAM2, 18 h) with (1) or without (2) ATc.”
BackgroundMethodInfluentialKesete, Y. (2020) · medRxiv · doi:10.1101/2020.02.11.20021279 · Cited by 5
“In the absence of treatment with anti-TB drugs, a study found (conducted before drug treatments became available) that about 70% of individuals with sputum smear-positive pulmonary TB died within 10 years of being diagnosed, as did about 20% of people with culture-positive (but smear-negative) pulmonary TB [5].”
BackgroundWhen Infections Don’t Reflect Infectiousness: Interpreting Contact Investigation Data With Care
Kendall, E. A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1144 · Cited by 5
“In some HIV-negative individuals, TB may even resolve without ever being diagnosed or treated [10].”
BackgroundSotgiu, G., Glaziou, P., Sismanidis, C., & Raviglione, M. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00507-5 · Cited by 5
Park, H., Kwon, J., Kim, H., Kwon, S., Nam, J. H., Min, S., Oh, I., Bea, S., & Choi, S. H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e167 · Cited by 4
Hailemariam, T. G., Tilahun, M., Atnafu, A., Gelanew, T., Gebresilase, T. T., Tola, M. A., Ayele, A., Moga, S., Shibeshi, W., Bobosha, K., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1512580 · Cited by 4
Davies‐Barrett, A. M., Casna, M., & Inskip, S. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324045 · Cited by 4
“While the average duration of untreated HIV-negative tuberculosis before death or resolution is around 3 years [125], tuberculosis can also cause acute pneumonia [126].”
Estimating the proportion of tuberculosis recent transmission via simulation
Kasaie, P., Dowdy, D. W., & Kelton, W. D. (2014) · Winter Simulation Conference · doi:10.1109/wsc.2014.7020000 · Cited by 4
“… Natural mortality rates Age-specific mortality rates for India (World Health Organization 2013a) ATB mortality rate 0.12 per year (Tiemersma et al. 2011) Annual primary infection rate (year 1 to 5 post infection) (8.66, 3.55, 1.12, 0.74, 0.24)% (Vynnycky & Fine 1997)…”
BackgroundInfluentialOutcomes for people with TB by disease severity at presentation
Leavitt, S. V., Rodriguez, C. A., Bouton, T. C., Horsburgh, C. R., Wiesch, P. A. Z., Nichols, B. E., White, L. F., & Jenkins, H. E. (2024) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.23.0254 · Cited by 4
Zwerling, A. A., Veerasingam, E., Snyder, E., Schertzer, A., Travers, K., Pim, C., Pease, C., Finn, S., McElroy, L., Allen, J., et al. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100916 · Cited by 4
Keeping It in the Family: the Childhood Burden of Tuberculosis
Chorba, T. L., & Jereb, J. (2017) · Emerging infectious diseases · doi:10.3201/eid2303.ac2303 · Cited by 4
Seifert, M., Capparelli, E. V., Catanzaro, D. G., & Rodwell, T. C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00076-19 · Cited by 4
“Prior to the advent of antimicrobials, the 10-year case fatality rate (CFR) for individuals with smear-positive tuberculosis (TB) was estimated to be 70% (1).”
BackgroundOptimizing hospital distribution across districts to reduce tuberculosis fatalities
Lee, M. J., Kim, K., Son, J., & Lee, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-65337-x · Cited by 4
Kaushik, S., Selvanathan, P., & Soni, G. V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267207 · Cited by 4
(2018) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2018.05.008 · Cited by 4
Disseminated Tuberculosis Resulting in Septic Shock in an Immunocompetent Patient
Jaffet, M. F., Abubakar, M., Ibrahim, Y. W., Ogbuneke, U., & Wahoo, W. (2022) · Cureus · doi:10.7759/cureus.28025 · Cited by 4
“In countries with low incidence and prevalence of mycobacteria tuberculosis infection, diagnosis is often delayed with increased morbidity and mortality [4-5].”
BackgroundSvadzian, A., Daniels, B., Sulis, G., Das, J., Daftary, A., Kwan, A. T., Das, V., Das, R., & Pai, M. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001898 · Cited by 4
“Failing to identify these persons results in continued community transmission, undermining national and global TB control efforts [3].”
BackgroundSurvival of people with untreated TB: effects of time, geography and setting
Rodriguez, C. A., Leavitt, S. V., Bouton, T. C., Horsburgh, C. R., Wiesch, P. A. Z., Nichols, B. E., Jenkins, H. E., & White, L. F. (2023) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.22.0668 · Cited by 4
Havumaki, J., Warren, J. L., Zelner, J., Menzies, N. A., Calderon, R. I., Contreras, C. C., Lecca, L. W., Becerra, M. C., Murray, M. B., & Cohen, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293519 · Cited by 4
Depictions of Heroism in Battle and Anguish from Tuberculosis
Chorba, T. L., & Breedlove, B. (2016) · Emerging infectious diseases · doi:10.3201/eid2203.ac2203 · Cited by 4
Caminando junto a la tuberculosis
Ticona, E. (2019) · Anales de la Facultad de Medicina · doi:10.15381/anales.v80i1.15877 · Cited by 4
Spatial distribution of tuberculosis in Nigeria and its socioeconomic correlates
Daniel, O. J. (2017) · Lancaster EPrints (Lancaster University) · Cited by 6
Jasim, T. S., Khan, A. H., & Hindi, N. K. K. (2023) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_336_22 · Cited by 3
Liu, R., Zhang, F., Li, S., Liu, Q., Pang, Y., & Li, L. (2024) · Metabolomics · doi:10.1007/s11306-024-02194-z · Cited by 3
“(Tiemersma et al., 2011).”
Batani, J., Nkomo, W., & Mokhosi, R. (2026) · Informatics and Health · doi:10.1016/j.infoh.2026.02.001 · Cited by 3
Koele, S. E., van Beek, S. W., Maartens, G., Brust, J. C. M., & Svensson, E. M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01749-21 · Cited by 3
Borregón, M., Sánchez, D., & Martínez, E. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03433-4 · Cited by 3
“Most people with an intact immune system will not develop active disease, but around 5–10% of infected people may develop active tuberculosis throughout their life [5–7].”
Eyawo, O., Lyzwinski, L. N., Ugoji, U. C., Pan, S., Sorkpor, S. K., Tawari-Fufeyin, P., & Hogg, R. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089507 · Cited by 3
Onu, D. U., Obi-keguna, C. N., Onyishi, I. E., & Igwe, E. J. (2025) · Psychology Health & Medicine · doi:10.1080/13548506.2025.2469195 · Cited by 6
“If untreated or poorly treated, it may persist for months or even years, with ongoing symptoms and long-term health effects (Mpoh, 2023; Tiemersma et al., 2011; World Health Organization, 2019).”
Risk factors for postoperative complications in patients with pulmonary tuberculosis
Wang, B., Yao, L., Sheng, J., Liu, X., Jiang, Y., Shen, L., Xu, F., Liu, Q., Bao, S., Gao, C., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02633-0 · Cited by 3
“Without proper treatment, TB carries a high mortality rate—around 50% [2].”
Modelling the HIV-Associated TB Epidemic and the Impact of Interventions Aimed at Epidemic Control
Dodd, P. J., Pretorius, C., & Williams, B. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-29108-2_3 · Cited by 3
Self-citation(2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71321-7.50016-1 · Cited by 4
Multidrug-Resistant Tuberculosis in Imo State, Southeast, Nigeria
Ahiarakwem, I. I., Ekejindu, I. M., Akujobi, C. N., & Aghanya, I. N. (2020) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_192_19 · Cited by 3
Nonlinear system for cell population growth simulations in pulmonary tuberculosis infection
Dewiyanti, U., Noviantri, V., & Rumagit, R. Y. (2023) · Procedia Computer Science · doi:10.1016/j.procs.2022.12.158 · Cited by 3
Singh, M., Bhatia, R., Devaraju, M., Ghuman, M., Muniyandi, M., Chauhan, A., Kaur, K., Rana, M., Pradhan, P., & Saini, S. (2023) · Journal of Pediatric Pulmonology · doi:10.4103/jopp.jopp_13_22 · Cited by 3
Zhou, Y., Qiu, Z., Dong, B., Yang, Y., Wang, Q., Yang, T., Zhang, J., He, Z., Zhang, X., Li, J., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135212 · Cited by 3
Yismaw, L., Zewotir, T. T., Muluneh, E. K., Getnet, F., Bitew, K. G., Abebe, H., Zewale, T. A., Tariku, M. K., Asrat, A., Andualem, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331035 · Cited by 3
“The result is worsened outcomes, especially concerning increased mortality and DALYs [109].”
Immunoregulatory Role of GM-CSF in Pulmonary Tuberculosis
Zisis, C., & Jagannath, C. (2012) · InTech eBooks · doi:10.5772/30003 · Cited by 3
“tuberculosis have contributed to the escalation of tuberculosis in recent years (4, 7-9).”
BackgroundChildhood tuberculosis in sub-Saharan Africa: A call to action
Eziyi Iche, K. A. L. U., Ojide, C. K., Nwadike, V. U., Korie, F. C., Ibeneme, C. A., & Okafor, G. O. C. (2015) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(15)60928-8 · Cited by 3
Yasin, M. (2016) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2016.03.00069 · Cited by 3
Kalo, D., Kant, S., Srivastava, K., & Sharma, A. (2017) · Lung India · doi:10.4103/0970-2113.201314 · Cited by 3
“According to studies, around 70% of patients with sputum smear-positive cases of pulmonary tuberculosis PTB, died within 10 years.[5] The disease takes no time spreading to other parts of the body viz.”
BackgroundTuberculosis Mastitis: Fever of Unknown Origin in a Kidney Transplant Recipient
Sarıbeyliler, G., Alimoglu, S. S., Mirioğlu, Ş., Demir, E., Çağatay, A., & Yazıcı, H. (2019) · European Journal of Breast Health · doi:10.5152/ejbh.2019.4488 · Cited by 3
Neurotuberculosis at the time of Anna O.: life prospects
Armocida, E., & Martini, M. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.013 · Cited by 3
Miller, A., Cairns, A., Richardson, A., & Lawrence, J. (2020) · Rural and Remote Health · doi:10.22605/rrh5552 · Cited by 3
Lolong, D. B., Tobing, K., Perwitasari, D., Pangaribuan, L., Tejayanti, T., & Oster Suryani, S. (2021) · Indian Journal of Public Health Research & Development · doi:10.37506/ijphrd.v12i3.16116 · Cited by 3
Kasaie, P., Sohn, H., Kendall, E. A., Gomez, G. B., Vassall, A., Pai, M., & Dowdy, D. W. (2017) · Winter Simulation Conference · doi:10.1109/wsc.2017.8247858 · Cited by 3
(2017) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2017.08.020 · Cited by 3
Sampaio, R. B. (2015) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2015.07.t.19126 · Cited by 3
Anderson, D. M., Charles, K. K., Olivares, C. L. H., & Rees, D. I. (2017) · National Bureau of Economic Research · doi:10.3386/w23219 · Cited by 7
“In a review of studies from the pre-chemotherapy era, Tiemersma et al. (2011) concluded that the duration of TB from onset to either cure or death was, on average, 3 years.”
Evaluating the impact of Xpert ® MTB/RIF on mortality from TB: are we asking the right questions?
Chani, K., Sekadde, M. P., Dlodlo, R. A., & Graham, S. M. (2022) · Public Health Action · doi:10.5588/pha.22.0021 · Cited by 3
Role of interleukin-22 in tuberculosis patients
Gupta, S., Banerjee, M., Gauba, K., Mitra, P., Shekhawat, J. K., Chauhan, N. K., Borana, H., Rao, M., Yadav, D., & Sharma, P. (2022) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2022-0106 · Cited by 2
Aşkın, F. N., Gazel, D., Fakılı, F., & Karslığil, T. (2025) · Mikrobiyoloji Bulteni · doi:10.5578/mb.202503158 · Cited by 2
Brümmer, L. E., Ryckman, T. S., Shrestha, S., Marx, F. M., Worodria, W. O., Christopher, D. J., Theron, G., Cattamanchi, A., Denkinger, C. M., Dowdy, D. W., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11905-3 · Cited by 2
“…by a more sensitive test would have lower bacillary loads; besides having lower current infectivity [11, 57], survival data from the pre-antibiotic data suggest such individuals have lower TB mortality risk [58], and models also translate this into less cumulative future transmission [12].”
Khoda, P., Sarkar, T. K., Prasad, S. N., & Meena, O. P. (2025) · Computational and Applied Mathematics · doi:10.1007/s40314-025-03543-x · Cited by 2
“Without treatment, TB has a case fatality rate of up to 50% (Tiemersma et al. 2011).”
Phillips, P. P. J., & Glidden, D. V. (2021) · Springer eBooks · doi:10.1007/978-3-319-52677-5_98-1 · Cited by 2
Saeed, I. K. M. A., & Abu, I. I. M. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4562903 · Cited by 2
Machlaurin, A., Luttjeboer, J., Setiawan, D., van der Werf, T. S., & Postma, M. J. (2023) · Journal of Global Health · doi:10.7189/jogh.13.04049 · Cited by 3
Olmesdahl, N.-P., Nel, C., MANNELL, A., & Fatman, L. (2023) · Acta Cytologica · doi:10.1159/000534193 · Cited by 2
“This will prevent TB complications that burden an already under-resourced, overburdened healthcare system [22].”
BackgroundHayre, K., Takele, M. K., & Birri, D. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303797 · Cited by 2
Öhrnberg, I., Karlsson, L., Sayyab, S., Paues, J., Martínez-Enguita, D., Gustafsson, M., Espinoza‐Lopez, P., Méndez‐Aranda, M., Meza, E., Ugarte‐Gil, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80570-4 · Cited by 2
Ryuk, D. K., Pelissari, D. M., Alves, K. B. A., Harada, L. O., Oliveira, P. B., Johansen, F. D. C., Maciel, E. L. N., Castro, M. C., Cohen, T., Sanchez, M. N., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018822 · Cited by 2
Ramachandran, G., & Swaminathan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00036-0 · Cited by 3
Kılıç, M. (2024) · doi:10.69860/nobel.9786053358930.9 · Cited by 2
Regulation of Envelope Stress Responses by Mycobacterium tuberculosis
Bretl, D. J., & Zahrt, T. C. (2016) · ASM Press eBooks · doi:10.1128/9781555818524.ch24 · Cited by 2
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.